publication . Article . 2011

Seguridad de la terapia de interferón alfa 2b recombinante más ribavirina en la hepatitis crónica C Safety of recombinant interferon alpha 2b plus ribavirin in chronic hepatitis C

Yoan Antonio Sánchez Rodríguez; Enrique Arús Soler; Pedro López Saura; Hugo Nodarse Cuní;
Open Access Spanish
  • Published: 01 Mar 2011 Journal: Revista Cubana de Farmacia, volume 45, issue 1, pages 34-43 (issn: 0034-7515, eissn: 1561-2988, Copyright policy)
  • Publisher: Editorial Ciencias Médicas
Abstract
INTRODUCCIÓN: la hepatitis crónica C ha adquirido rango de pandemia. El virus de la hepatitis C se ha convertido en la causa principal de hepatitis crónica, cirrosis hepática, hepatocarcinoma, y trasplante de hígado a nivel mundial. OBJETIVO: identificar los efectos adversos asociados a la terapia combinada interferón alfa 2b recombinante más ribavirina durante la evolución del tratamiento y hasta 8 semanas después de finalizado, así como los principales efectos asociados a salidas temporales o definitivas de esta terapia. MÉTODOS: estudio de farmacovigilancia cuya serie estuvo conformada por 122 pacientes con hepatitis crónica C atendidos en el Instituto de Gas...
Subjects
free text keywords: Hepatitis crónica C, interferón alfa 2b, ribavirina, síndrome seudogripal, anemia, Chronic hepatitis C, interferon alpha 2b, ribavirin, pseudocold syndrome, lcsh:Therapeutics. Pharmacology, lcsh:RM1-950
Download from
27 references, page 1 of 2

1. Moreno OR, Diago M. Situaciones clínicas en el manejo de las hepatitis virales. Madrid: Grupo Acción Médica; 2005. p .3-207.

2. Common Toxicity Criteria, version 2. Bethestda, Md: National Cancer Institute. 1999. Accessed Dec 15 2004. Available from http://ctep.info.nih.gov

3. Gervais A, Boyer N, Marcellin P. Tolerability of treatments for viral hepatitis. Drug Saf. 2001;24(5):375-84.

4. Davis GL, Esteban-Mur R, Rustgi V. Interferon alpha-2b alone in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493-9.

5. Dieperink E, Willenbring M, Ho S. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psych. 2000;157(6):867-76.

6. Malaguarnera M, Di Fazio I, Restuccia S. Interferon alpha-induced depression in chronic hepatitis C patients:comparison between different types of interferon alpha. Neuropsychobiology. 1998;37:93-97.

7. Nesic Z, Delic D, Prostran M. Psychiatric adverse effects induced by recombinant interferon alpha in patients with chronic hepatitis C. Med Pregl. 2004 MayJun;57(5-6):219-26. [OpenAIRE]

8. Pawlotsky JM, Dahari H, Neumann AU. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004 Mar;126(3):703-14.

9. De Franceschi L, Fattovich G, Turrini F. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection : role of membrane oxidative damage. Hepatology. 2000;31:997-1004.

10. Soza A, Everhart JE, Ghany MG. Neutropenia during combination therapy of interferon alpha and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273-9.

11. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med. 2004 May;71Suppl3:S17-21

12. Tod M, Farcy- Afif M, Stocco J. Pharmacokinetic/pharmacodynamic and time-toevent models of ribavirin-induced anemia in chronic hepatitis C. Clin Pharmacokinet. 2005;44(4):417-28.

13. McHutchison JG, Gordon SC, Schiff ER. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-92.

14. Rebetron (combination therapy containing rebetol [Ribavirin, USP] capsules and Intron A [interferon alpha-2b, recombinant injection]) prescribing information. Kenilworth: Shering; 2001.

15. Hsieh MC, Yu ML, Chuang WL. Virologic factors related to interferon-alphainduced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol. 2000;142:431-7.

27 references, page 1 of 2
Any information missing or wrong?Report an Issue